Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma

In this edition of The Rob & Jai Show , the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway. Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses: The evolution of his career from medical device sales to surgical commercialization and C-suite leadership. Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that. The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass. The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate. Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond. Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

Listen